查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1699059

门诊肿瘤输液市场成长、规模和趋势分析（按产品、应用、疗法和模式）—区域展望、竞争策略和细分预测（至 2034 年）

Outpatient Oncology Infusion Market Growth, Size, Trends Analysis - By Product, By Application, By Therapy, By Mode - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 260 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2034 年全球门诊肿瘤输液市场规模将达到 74.6 亿美元，复合年增长率为 10.86%。

门诊肿瘤输注是指在门诊进行无需住院的癌症治疗，如免疫治疗、化疗、标靶治疗等。患者在诊所、门诊护理中心或专门输液中心的医疗监督下接受输液治疗。该策略在确保安全有效的治疗的同时，提高了患者的便利性，降低了医疗成本，并缩短了住院时间。

治疗费用高、报销程序复杂以及患者的经济限制是市场面临的一些挑战。肿瘤科护理师和药剂师的短缺使得服务提供变得更具挑战性。此外，还需要严格的程序和监控来限制药物不良反应并确保门诊病人的安全。

本报告调查了全球门诊肿瘤输液市场，并提供了市场的全面概述、市场影响因素和市场机会的分析、市场规模的趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局以及主要企业的概况。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场动态

  • 驱动因素、阻碍因素、机会与挑战分析

第五章 市场变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争格局

  • 製造地、销售区域、产品类型分布
  • 併购、合作、产品发布与合作

7. 全球门诊肿瘤输液市场（依产品）

  • 点滴帮浦
  • 静脉注射套件
  • 静脉插管
  • 无针头连接器

8. 全球门诊肿瘤输液市场（依应用）

  • 肺癌
  • 肝癌
  • 乳癌
  • 摄护腺癌

9. 全球门诊肿瘤输液市场（依治疗方法）

  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 荷尔蒙疗法

第十章全球门诊肿瘤输液市场（按模式）

  • 肌肉注射（IM）
  • 静脉注射（IV）
  • 皮下

第 11 章全球门诊肿瘤输液市场

  • 全球门诊肿瘤输液市场规模及市场占有率

第 12 章全球门诊肿瘤输液市场（按地区）

  • 亚太地区
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • UAE
    • 卡达
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亚
    • 其他的
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美国
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他的

第十三章 公司简介

  • B. Braun Melsungen AG
  • Baxter
  • Becton, Dickinson, and Company
  • Fresenius Kabi
  • ICU Medical, Inc
  • IRadimed Corporation
  • Medtronic PLC
  • Micrel Medical Devices SA
  • Moog, Inc.
  • Nipro Corporation
  • 其他的

第十四章结论

第 15 章简称表

第十六章参考连结

简介目录
Product Code: HLCA2582

Outpatient Oncology Infusion Market Introduction and Overview

According to SPER market research, 'Global Outpatient Oncology Infusion Market Size- By Product, By Application, By Therapy, By Mode - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Outpatient Oncology Infusion Market is predicted to reach 7.46 billion by 2034 with a CAGR of 10.86%.

Outpatient oncology infusion represents the delivery of cancer treatments, such as immunotherapy, chemotherapy, or targeted therapy, in an outpatient setting without the need for hospital. Patients get intravenous drugs under medical supervision at clinics, ambulatory care centres, or specialist infusion centres. While ensuring safe and efficient treatment, this strategy improves patient convenience, lowers medical costs, and shortens hospital stays.

Restraints: High treatment costs, complicated reimbursement procedures, and patient financial constraints are some of the issues facing the outpatient oncology infusion business. Service delivery is further strained by a lack of qualified oncology nurses and pharmacists. Strict procedures and oversight are also necessary for controlling adverse medication responses and guaranteeing patient safety in outpatient settings.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By Application, By Therapy, By Mode.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

      • B. Braun Melsungen AG, Baxter, Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc, IRadimed Corporation, Medtronic PLC, Micrel Medical Devices SA, Moog, Inc., Nipro Corporation. and others.

Outpatient Oncology Infusion Market Segmentation:

By Product: Based on the Product, Global Outpatient Oncology Infusion Market is segmented as; Infusion pumps, Intravenous sets, IV cannulas, Needleless connectors.

By Application: Based on the Application, Global Outpatient Oncology Infusion Market is segmented as; Lung cancer, Liver cancer, Breast cancer, Prostate cancer.

By Therapy: Based on the Therapy, Global Outpatient Oncology Infusion Market is segmented as; Chemotherapy, Targeted therapy, Immunotherapy, Hormonal therapy.

By Mode: Based on the Mode, Global Outpatient Oncology Infusion Market is segmented as; Intramuscular (IM), Intravenous (IV), Subcutaneous.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPERs internal database
    • 2.1.4. Premium insight from KOLs
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTERs Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Outpatient Oncology Infusion Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Outpatient Oncology Infusion Market

7. Global Outpatient Oncology Infusion Market, By Product (USD Million) 2021-2034

  • 7.1. Infusion pumps
  • 7.2. Intravenous sets
  • 7.3. IV cannulas
  • 7.4. Needleless connectors

8. Global Outpatient Oncology Infusion Market, By Application (USD Million) 2021-2034

  • 8.1. Lung cancer
  • 8.2. Liver cancer
  • 8.3. Breast cancer
  • 8.4. Prostate cancer

9. Global Outpatient Oncology Infusion Market, By Therapy (USD Million) 2021-2034

  • 9.1. Chemotherapy
  • 9.2. Targeted therapy
  • 9.3. Immunotherapy
  • 9.4. Hormonal therapy

10. Global Outpatient Oncology Infusion Market, By Mode (USD Million) 2021-2034

  • 10.1. Intramuscular (IM)
  • 10.2. Intravenous (IV)
  • 10.3. Subcutaneous

11. Global Outpatient Oncology Infusion Market, (USD Million) 2021-2034

  • 11.1. Global Outpatient Oncology Infusion Market Size and Market Share

12. Global Outpatient Oncology Infusion Market, By Region, (USD Million) 2021-2034

  • 12.1. Asia-Pacific
    • 12.1.1. Australia
    • 12.1.2. China
    • 12.1.3. India
    • 12.1.4. Japan
    • 12.1.5. South Korea
    • 12.1.6. Rest of Asia-Pacific
  • 12.2. Europe
    • 12.2.1. France
    • 12.2.2. Germany
    • 12.2.3. Italy
    • 12.2.4. Spain
    • 12.2.5. United Kingdom
    • 12.2.6. Rest of Europe
  • 12.3. Middle East and Africa
    • 12.3.1. Kingdom of Saudi Arabia
    • 12.3.2. United Arab Emirates
    • 12.3.3. Qatar
    • 12.3.4. South Africa
    • 12.3.5. Egypt
    • 12.3.6. Morocco
    • 12.3.7. Nigeria
    • 12.3.8. Rest of Middle-East and Africa
  • 12.4. North America
    • 12.4.1. Canada
    • 12.4.2. Mexico
    • 12.4.3. United States
  • 12.5. Latin America
    • 12.5.1. Argentina
    • 12.5.2. Brazil
    • 12.5.3. Rest of Latin America

13. Company Profile

  • 13.1. B. Braun Melsungen AG
    • 13.1.1. Company details
    • 13.1.2. Financial outlook
    • 13.1.3. Product summary
    • 13.1.4. Recent developments
  • 13.2. Baxter
    • 13.2.1. Company details
    • 13.2.2. Financial outlook
    • 13.2.3. Product summary
    • 13.2.4. Recent developments
  • 13.3. Becton, Dickinson, and Company
    • 13.3.1. Company details
    • 13.3.2. Financial outlook
    • 13.3.3. Product summary
    • 13.3.4. Recent developments
  • 13.4. Fresenius Kabi
    • 13.4.1. Company details
    • 13.4.2. Financial outlook
    • 13.4.3. Product summary
    • 13.4.4. Recent developments
  • 13.5. ICU Medical, Inc
    • 13.5.1. Company details
    • 13.5.2. Financial outlook
    • 13.5.3. Product summary
    • 13.5.4. Recent developments
  • 13.6. IRadimed Corporation
    • 13.6.1. Company details
    • 13.6.2. Financial outlook
    • 13.6.3. Product summary
    • 13.6.4. Recent developments
  • 13.7. Medtronic PLC
    • 13.7.1. Company details
    • 13.7.2. Financial outlook
    • 13.7.3. Product summary
    • 13.7.4. Recent developments
  • 13.8. Micrel Medical Devices SA
    • 13.8.1. Company details
    • 13.8.2. Financial outlook
    • 13.8.3. Product summary
    • 13.8.4. Recent developments
  • 13.9. Moog, Inc.
    • 13.9.1. Company details
    • 13.9.2. Financial outlook
    • 13.9.3. Product summary
    • 13.9.4. Recent developments
  • 13.10. Nipro Corporation
    • 13.10.1. Company details
    • 13.10.2. Financial outlook
    • 13.10.3. Product summary
    • 13.10.4. Recent developments
  • 13.11. Others

14. Conclusion

15. List of Abbreviations

16. Reference Links